胶质瘤新型分子标志物的研究进展  

Research progress on novel molecular marker of glioma

作　　者：李晓蓉 王宏坤[2] 卞伟 郑绘霞[2] 肖虹[2] LI Xiaorong;WANG Hongkun;BIAN Wei;ZHENG Huixia;XIAO Hong(The First Clinical Medical College,Shanxi Medical University,Shanxi Province,Taiyuan 030000,China;Department of Pathology,the First Hospital of Shanxi Medical University,Shanxi Province,Taiyuan 030000,China)

机构地区：[1]山西医科大学第一临床医学院,山西太原030000 [2]山西医科大学第一医院病理科,山西太原030000

出　　处：《中国医药导报》2023年第25期62-65,共4页China Medical Herald

基　　金：山西省自然科学基金项目(201901D111210)。

摘　　要：胶质瘤是发病率和死亡率较高的颅内恶性肿瘤,给公众卫生健康造成巨大负担。目前仅依靠影像学和基于传统活检组织形态的病理分型已不能满足临床诊疗的需求。因此,亟须探索敏感性更高、特异性更强的辅助诊断工具,近年来分子标志物的临床应用成为研究热点,有助于明确疾病分型,确保早发现、早诊断、早治疗。本文总结了一些有潜力的遗传学分子标志物在疾病诊断和预后预测中的作用,旨在为胶质瘤临床应用奠定理论基础,使个体化精准治疗成为可能。Glioma is an intracranial malignant tumor with high morbidity and mortality,which causes a huge burden to public health.At present,relying solely on imaging and pathological classification based on traditional biopsy tissue morphology cannot meet the needs of clinical diagnosis and treatment.Therefore,it is urgent to explore auxiliary diagnostic tools with higher sensitivity and stronger specificity.In recent years,the clinical application of molecular marker has become a research hotspot,which helps to clarify disease classification and ensure early detection,diagnosis,and treatment.This article summarizes the potential roles of some genetic molecular markers in disease diagnosis and prognosis prediction,aiming to lay a theoretical foundation for the clinical application of glioma and make personalized and precise treatment possible.

关 键 词：胶质瘤 指南 诊断 分子标志物 

分 类 号：R739.4[医药卫生—肿瘤]